Optic neuritis: An update typical and atypical optic neuritis

Neuro-Ophthalmology

Volumn 32, Issue 5, 2008, Pages 237-248

  Hickman, Simon J ^a   Ko, Michael ^b   Chaudhry, Frasat ^b   Jay, Walter M ^b   Plant, Gordon T ^c  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^c NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

Multiple sclerosis; Neuromyelitis optica; Optic neuritis

Indexed keywords

AZATHIOPRINE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISOLONE; RITUXIMAB;

ALGORITHM; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DEMYELINATING DISEASE; DRUG DOSE REDUCTION; HUMAN; LOW DRUG DOSE; OPTIC NEURITIS; PATIENT CARE; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL FIELD;

EID: 54249090237     PISSN: 01658107     EISSN: 1744506X     Source Type: Journal    
DOI: 10.1080/01658100802391905     Document Type: Review

References (72)

1. Hickman SJ, Dalton CM, Miller DH, et al. Management of acute optic neuritis. Lancet 2002;360:1953-1962.
2. The Optic Neuritis Study Group. Multiple sclerosis risk after optic neuritis: Final Optic Neuritis Treatment Trial follow-up. Arch Neurol. 2008;65:727-732.
3. Fisniku LK, Brex PA, Altmann DR, et al. Disability and T2 MRI lesions: A 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008;131:808-817.
4. Pirko I, Blauwet LK, Lesnick TG, et al. The natural history of recurrent optic neuritis. Arch Neurol. 2004;61:1401-1405.
5. Kidd D, Burton B, Plant GT, et al. Chronic relapsing inflammatory optic neuropathy (CRION): A newly recognised steroid responsive syndrome seemingly distinct from sarcoidosis. Brain 2003;126:276-284.
6. Frohman EM, Frohman TC, Zee DS, et al. The neuroophthalmology of multiple sclerosis. Lancet Neurol. 2005;4:111-121.
7. Balcer LJ. Optic neuritis. N Engl J Med. 2006;354:1273-1280.
8. Rodriguez M, Siva A, Cross SA, et al. Optic neuritis: A population-based study in Olmsted County, Minnesota. Neurology 1995;45:244-250.
9. Jin YP, Pedro-Cuesta J, Soderstrom M, et al. Incidence of optic neuritis in Stockholm, Sweden 1990-1995: I. Age, sex, birth and ethnic-group related patterns. J Neurol Sci. 1998;159:107-114.
10. MacDonald BK, Cockerell OC, Sander JW, et al. The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK. Brain 2000;123:665-676.
11. Davis FA, Bergen D, Schauf C, et al. Movement phosphenes in optic neuritis: A new clinical sign. Neurology 1976;26:1100-1104.
12. Keltner JL, Johnson CA, Spurr JO, et al. Baseline visual field profile of optic neuritis. The experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol 1993;111:231-234.
13. Optic Neuritis Study Group. The clinical profile of optic neuritis: Experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol. 1991;109:1673-1678.
14. Phillips PH, Newman NJ, Lynn MJ. Optic neuritis in African Americans. Arch Neurol. 1998;55:186-192.
15. Perkin GD, Rose FC. Optic Neuritis and Its Differential Diagnosis. Oxford: Oxford University Press; 1979.
16. Hickman SJ, Toosy AT, Miszkiel KA, et al. Visual recovery following acute optic neuritis: A clinical, electrophysiological and magnetic resonance imaging study. J Neurol. 2004;251:996-1005.
17. Beck RW, Cleary PA, Optic Neuritis Study Group. Optic Neuritis Treatment Trial: One-year follow-up results. Arch Ophthalmol. 1993;111:773-775.
18. Brusa A, Jones SJ, Plant GT. Long-term remyelination after optic neuritis: A 2-year visual evoked potential and psychophysical serial study. Brain 2001;124:468-479.
19. Wakakura M, Minei-Higa R, Oono S, et al. Baseline features of idiopathic optic neuritis as determined by a multicenter treatment trial in Japan. Jpn J Ophthalmol. 1999;43:127-132.
20. Wakakura M, Mashimo K, Oono S, et al. Multicenter clinical trial for evaluating methylprednisolone pulse treatment of idiopathic optic neuritis in Japan. Jpn J Ophthalmol. 1999;43:133-138.
21. Bee Y-S, Lin M-C, Wang C-C, et al. Optic neuritis: Clinical analysis of 27 cases. Kaohsiung J Med Sci. 2003;19:105-112.
22. Wang J-C, Tow S, Aung T, et al. The presentation, aetiology, management and outcome of optic neuritis in an Asian population. Clin Exp Ophthalmol. 2001;29:312-315.
23. Chuenkongkaew W, Chirapapaisan N. Optic neuritis: Characteristics and visual outcome. J Med Assoc Thai. 2003;86:238-243.
24. Singh Sethi H, Menon V, Sharma P, et al. Visual outcome after intravenous dexamethasone therapy for idiopathic optic neuritis in an Indian population: A clinical case series. Indian J Ophthalmol. 2006;54:177-183.
25. Pokroy R, Modi G, Saffer D. Optic neuritis in an urban black African community. Eye 2001;15:469-473.
26. Alvarez G, Cardenas M. Multiple sclerosis following optic neuritis in Chile. J Neurol Neurosurg Psychiatry 1989;52:115-117.
27. Beck RW. Optic Neuritis. In: Miller NR, Newman NJ, eds. Walsh and Hoyt's Clinical Neuro-Ophthalmology 5th ed. Baltimore: Williams and Wilkins. 1998; pp. 599-647.
28. Slamovits TL, Rosen CE, Cheng KP, et al. Visual recovery in patients with optic neuritis and visual loss to no light perception. Am J Ophthalmol. 1991;111:209-214.
29. Kupersmith MJ, Gal RL, Beck RW et al. Visual function at baseline and 1 month in acute optic neuritis: Predictors of visual outcome. Neurology 2007;69:508-514.
30. Compston A, Coles A. Multiple sclerosis. Lancet. 2002;359:1221-1231.
31. Hickman SJ. Optic nerve imaging in multiple sclerosis. J Neuroimaging 2007;17(Suppl.1):42S-45S.
32. Trip SA, Schlottmann PG, Jones SJ, et al. Retinal nerve fiber layer axon loss and visual dysfunction in optic neuritis. Ann Neurol. 2005;58:383-391.
33. Toosy AT, Hickman SJ, Miszkiel KA, et al. Adaptive cortical plasticity in higher visual processing areas after acute optic neuritis. Ann Neurol. 2005;57:622-633.
34. Frohman EM, Costello F, Stuve O, et al. Modeling axonal degeneration within the anterior visual system: Implications for demonstrating neuroprotection in MS. Arch Neurol. 2008;65:26-35.
35. The Optic Neuritis Study Group. Visual function more than 10 years after optic neuritis: Experience of the Optic Neuritis Treatment Trial. Am J Ophthalmol. 2004;137:77-83.
36. Optic Neuritis Study Group. Visual function 15 years after optic neuritis: A final follow-up report from the optic neuritis treatment trial. Ophthalmology 2008;115:1079-1082.
37. de la Cruz J, Kupersmith MJ. Clinical profile of simultaneous bilateral optic neuritis in adults. Br J Ophthalmol. 2006;90:551-554.
38. Beck RW, Cleary PA, Anderson MM Jr, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med. 1992;326:581-588.
39. Newman NJ, Lessell S, Winterkorn JM. Optic chiasmal neuritis. Neurology 1991;41:1203-1210.
40. da Silva Costa RM, Santos AC, Costa LS. An unusual chiasmal visual defect in a patient with neuromyelitis optica: Case report. Arq Bras Oftalmol. 2007;70:153-155.
41. Vedula SS, Brodney-Folse S, Gal RL, et al. Corticosteroids for treating optic neuritis. Cochrane Database of Systematic Reviews. 2007, Issue 1. Art. No.: CD001430.
42. Sellebjerg F, Nielsen HS, Frederiksen JL, et al. A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis. Neurology 1999;52:1479-1484.
43. Beck RW, Cleary PA, Trobe JD, et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. N Engl J Med. 1993;329:1764-1769.
44. Kupersmith MJ, Burde RM, Warren FA, et al. Autoimmune optic neuropathy: Evaluation and treatment. J Neurol Neurosurg Psychiatry 1988;51:1381-1386.
45. Purvin V, Kawasaki A, Jacobson DM. Optic perineuritis: Clinical and radiographic features. Arch Ophthalmol. 2001;119:1299-1306.
46. Papais-Alvarenga RM, Carellos SC, Alvarenga MP, et al. Clinical course of optic neuritis in patients with relapsing neuromyelitis optica. Arch Ophthalmol. 2008;126:12-16.
47. Galindo-Rodríguez G, Aviña-Zubieta JA, Pizarro S, et al. Cyclophosphamide pulse therapy in optic neuritis due to systemic lupus erythematosus: An open trial. Am J Med. 1999;106:65-69.
48. Koczman JJ, Rouleau J, Gaunt M, et al. Neuro-ophthalmic sarcoidosis: The University of Iowa experience. Semin Ophthalmol. 2008;23:157-168.
49. Kansu T, Kirkali P, Kansu E, et al. Optic neuropathy in Behcet's disease. J Clin Neuro-Ophthalmol. 1989;9:277-280.
50. Merle H, Smadja D, Merle S, et al. Visual phenotype of multiple sclerosis in the Afro-Caribbean population and the influence of migration tometropolitan France. Eur J Ophthalmol. 2005;15:392-399.
51. Wingerchuk DM, Lennon VA, Lucchinetti CF, et al. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6:805-815.
52. Kira J. Multiple sclerosis in the Japanese population. Lancet Neurol. 2003;2:117-127.
53. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: Distinction from multiple sclerosis. Lancet 2004;364:2106-2112.
54. Lennon VA, Kryzer TJ, Pittock SJ, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin 4 water channel. J Exp Med. 2005;202:473-477.
55. Marignier R, de Sèze J, Vukusic S, et al. NMO-IgG and Devic's neuromyelitis optica: A French experience. Mult Scler. 2008;14:440-445.
56. Paul F, Jarius S, Aktas O, et al. Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med. 2007;4:e133.
57. de Seze J, Arndt C, Jeanjean L, et al. Relapsing inflammatory optic neuritis: Is it neuromyelitis optica? Neurology 2008;70:2075-2076.
58. Matiello M, Lennon VA, Jacob A, et al. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology 2008;70:2197-2200.
59. Kikuchi S, Fukazawa T. OSMS is NMO, but not MS: Confirmed by NMO-IgG? Lancet Neurol. 2005;4:594-595.
60. Matsuoka T, Matsushita T, Kawano Y, et al. Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese. Brain 2007;130:1206-1223.
61. Tanaka M, Tanaka K, Komori M, et al. Anti-aquaporin 4 antibody in Japanese multiple sclerosis: The presence of optic-spinal multiple sclerosis without long spinal cord lesions and anti-aquaporin 4 antibody. J Neurol Neurosurg Psychiatry. 2007;78:990-992.
62. Hickman SJ. Inflammatory optic neuropathies. In: Roy FH, Fraunfelder FW and Fraunfelder FT eds: Current Ocular Therapy 6th ed. Saunders Elsevier 2008; pp. 578-581.
63. Beck RW, Cleary PA, Backlund JC. The course of visual recovery after optic neuritis. Experience of the Optic Neuritis Treatment Trial. Ophthalmology 1994;101:1771-1778.
64. Ruprecht K, Klinker E, Dintelmann T, et al. Plasma exchange for severe optic neuritis: Treatment of 10 patients. Neurology 2004;63:1081-1083.
65. Weinshenker BG, O'Brien PC, Petterson TM, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol. 1999;46:878-886.
66. Watanabe S, Nakashima I, Misu T, et al. Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler. 2007;13:128-132.
67. Roed HG, Langkilde A, Sellebjerg F, et al. A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis. Neurology 2005;64:804-810.
68. Noseworthy JH, O'Brien PC, Petterson TM, et al. A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology 2001;56:1514-1522.
69. Bakker J, Metz L. Devic's neuromyelitis optica treated with intravenous gamma globulin (IVIG). Can J Neurol Sci. 2004;31:265-7.
70. Watanabe S, Misu T, Miyazawa I. Low-dose corticosteroids reduce relapses in neuromyelitis optica: A retrospective analysis. Mult Scler. 2007;13:968-974.
71. Giovannoni G. To test or not to test: NMO-IgG and optic neuritis. Neurology 2008;70:2192-2193.
72. Cree BAC, Lamb S, Morgan K. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005;64:1270-1272.